The usefulness, complications and reasons for discontinuing the self-injection program with a combination of papaverine, phentolamine and prostaglandin E 1 were evaluated in 189 patients (mean age 57.2 y), who were included from April 1993 to September 1995 (mean follow-up 10.25 months).
Introduction
A self-injection program with vasoactive drugs (VAS) for the treatment of sexual erectile dysfunction (SED) is a widely used and recognised method. 1±5 Several drugs have been employed, including papaverine with or without phentolamine, 6 prostaglandin E 1 (PGE 1 ) 7 and more recently the combination of these drugs. 8 The aim of the present work was to evaluate the usefulness of a mixture of three vasoactive drugs (TRIMIX), the complications associated with its use, and the reasons for discontinuing treatment with VAS.
Patients and methods
During the period from April 1993 to September 1995, a total of 189 patients with SED, whose average age was 57.2 y (range 27±78 y), were evaluated and included in a VAS program with TRIMIX.
Diagnostic studies carried out included psychosexual, vascular (pharmacological erection test, penile color¯ow duplex ultrasonography, cavernosometry-cavernosography), neurological (emg-cc, somatic nerves evaluation) and endocrinological (free testosterone and prolactin) evaluation, as well as determination of nocturnal erections with Rigiscan (Dacomed Corp., Minneapolis, Minnesota, USA), with due attention to individual patient features as previously described. 9 Organic pathology was diagnosed in 105 patients (55.6%), while SED was purely functional in the remaining 84 (44.4%). Forty-six patients (24.3%) were treated concomitantly with sexual therapy.
The organic group was constituted by 72 patients with vascular pathology, 21 diabetics, 7 neurologics and 5 with pelvic traumatism.
The dose of trimix to be taken by the patients was determined after a phase of progressive testing, starting with 0.25 ml in functionals and with 0.50 ml in organic patients. This dose was gradually increased or decreased until they reached a rigidity that would enable a penetration of at least 20 min. All the patients were injected and they underwent and erotic manual and visual stimulation for 15 min. The response was evaluated by the physician in charge.
Once VAS dose was determined and method training was completed, patients were recalled for quarterly control as already described.
Throughout, a mixture of vasoactive drugs (TRI-MIX) was employed, prepared as follows: 17.64 mg/ml of papaverine hydrochloride, 0.58 mg/ml of phentolamine mesilate and 5.8 mm/ml of PGE 1 .
According to follow-up ®ndings, patients were split into two groups: (a) Active Group, those who continued with the VAS program as treatment for their dysfunction; and (b) Inactive Group, those who failed to attend control after ®ve months from the last consultation or who at successive controls expressed their decision to discontinue treatment. We have not included in the inactive group those patients who had to discontinue treatment due to complications following the VAS program.
Surveys were conducted in order to detect the causes of discontinuing the VAS program of the inactive group, which were performed during consultation or by telephone.
Results
The active group was made up by 91 patients (48%), out of whom 66 (72.6%) presented organic and 25 (27.4%) functional pathology.
The inactive group comprised 98 patients (52%), 39 (40%) with organic and 59 (60%) with functional pathology.
Concomitantly, sexual therapy was carried out on 27 patients belonging to the active group (29.7%) and on 19 of the inactive group (19.4%).
Mean follow-up was 10.25 months for the global population, 16.95 for the active group and 4.32 months for the inactive group.
Out of the total number of patients included in the VAS program, the triple mixture maintained active response in 159 (84.4%) during the observation period.
The mean dose of TRIMIX employed at the beginning and end of the treatment was 0.58 and 0.42 ml, respectively with an average time of dose variation of 3.22 months. This decreasing trend was also discerned in the active group (0.55±0.43 ml) as well as in the inactive group (0.46±0.31 ml). Patients with functional pathology presented a mean dose variation of 0.59±0.28 ml, while for those with organic pathology it was of 0.59±0.55 ml.
Out of the surveyed patients in the inactive group, 50 (51%) responded, 19 in consultation and 31 by telephone.
Reported causes of discontinuance were: (a) recovery of spontaneous erections in 15 (30%); (b) inability to achieve erections suitable for penetration in 15 (30%); (c) rejection of the method in 10 (20%); (d) loss of the sexual partner in 5 (10%); (e) development of further dysfunction (either of desire or of ejaculation) preventing sexual activity in 3 (6%); and (f) severe deterioration in general status in 2 (4%) ( Table 1) .
Out of the group of patients reporting failure to achieve good response with TRIMIX, 67% presented organic pathology as a cause of their dysfunction, while among those who recovered rigid erections, 93% were functional cases ( Table 2) .
Complications observed in the total patient population on the VAS program (n 189) were as follows: echymosis or hematomas at the injection site (20.1%), ®brosis (5.3%), prolonged erections lasting over 3 hours (3.7%) and urethral bleeding (1.1%). Prolonged erection episodes resolved within 12 h after onset of the symptom, and no cases presented evidence of ®brosis in the cavernous bodies as a sequela.
The 10 patients who presented ®brosis, which appeared after 3±9 months of treatment, were selfinjecting doses ranging from 0.125±0.75 ml. Out of these, 50% presented diffuse cavernous ®brosis, located in all cases on the homolateral side on the punctions site, with a variable extension ranging from 2±4 cm while the other 50% had subalbugineous nodules.
None of the patients on the VAS program complained of pain during the therapeutic phase.
Discussion
The ideal vasoactive drug must be easy to apply and manipulate both for the physician and for the patient, possessing a high therapeutic index and a wide therapeutic range, as well as lacking pharmacological interactions, toxic or adverse effects. Obviously enough, such a drug is not yet available.
In theory, the low volumes employed when using mixtures of 3 or more vasoactive drugs would be expected to reduce the frequency of undesirable Drop-out reasons and complications in self-injection therapy A Casabe Â et al side-effects of each particular drug, as for instance the pain associated with erection when resorting to PGE 1 alone. 10 Furthermore, the diverse levels of action on the mechanism of erection exerted by each one of these drugs would presumably enhance their joint ef®cacy by acting synergically. 11 In our experience one ml of TRIMIX proved more effective than 40 mg of PGE 1 in non-responders to high doses of papaverine and phentolamine. 10 In our population, the triple mixture proved to be effective in roughly 85% of the patients followed up, a ®gure comparable to those reported by other authors. 12 The most noteworthy observation in the present series was the great number of patients who discontinued the VAS program (52%), which could explain the low mean follow-up period (10.25 months) in a population under observation for over two years. This ®nding has been previously described with lower percentages ranging from 12± 50%, 13±17 a difference attributable to the composition of studied populations, in which the percentage of patients with functional pathology was lower than 10%, considerably less than the 44.4% percentage recorded in our present series.
However, in a series of 140 patients on a selfinjection program with papaverine plus phentolamine or prostaglandin E 1 , with a mean follow-up of 11 months and a population comprising only 20% of functional patients, Weiss et al 18 communicated a discontinuance rate of 80%.
On evaluating patients receiving complementary sexual therapy, a greater trend to remain on the VAS program was observed. However, it is dif®cult to claim the superiority of the combined treatment since to establish comparable groups speci®c parameters would be required to measure conditioning psychological and marital factors pertinent to each patient. Strikingly, there are indeed few reports documenting the rate of treatment discontinuance in patients receiving sexual therapy alone. Some authors contend that no signi®cant differences could be found in the rate of treatment discontinuance in cases with concomitant sexual therapy versus those without. 19 With respect to the causes of desertion, we observed that the group reporting inability to achieve erections suitable for penetration made up 30% of the surveyed population. This might suggest that in such cases TRIMIX had lost its ef®ciency, but this is hardly tenable as it was not checked by the attending physician, since other feasible factors such as inappropriate drug use by de®cient application technique, faulty preservation and/or insuf®cient dosing could also explain the poor response achieved. However, there is the possibility that the considerable number of patients with organic pathology in this group (67%) could have worsened their disease, thus becoming refractory to vasoactive drugs.
It is worth mentioning, we have not considered drop-outs, those 5 patients who had to discontinue the VAS program with (TRIMIX) due to the development of a ®brotic process in the cavernous body.
Causes of discontinuance unrelated to the ef®-ciency of TRIMIX (70%) were found for the most part among cases of functional pathology.
Within this group, one third of the patients recovered erections suitable for penetration, out of whom 93% presented functional pathology.
On appraising dose variation according to dysfunction diagnosis, patients with functional pathology markedly decreased the dose employed (from 0.59±0.28 ml), whereas patients with organic pathology failed to present signi®cant variations (from 0.58 ±0.55 ml). The coincidence in the mean initial dose was accidental, probabily due to the low dose used in neurological patients and to the high dose necessary to achieve the erection in the functional patients.
Among the neurological patients we have also included the diabetics and the pelvic traumatised, with a possible neurological erectile dysfunction.
On the other hand, we believed a high dose was necessary in the functional group due to the high adrenergic tone at the beginning of the treatment. This group probably experinced lesser anxiety, an increase in their self-esteem, and the assurance brought about by the recovery of erections that allow penetration, even if they were pharmacologically obtained. These reasons could account for the signi®cant progressive decrease of their dose.
On the basis of our results, it may be highlighted that the functional group was more liable to discontinue treatment within a period of four months due to causes unrelated to erectile response, to vary the dose signi®cantly or to recover spontaneous rigid erections suitable for penetration. This could be explained by the effect caused by impotence symptom reversion, which offsets the psychological mechanisms at work, although the de®nitive disappearance of the symptom cannot be ensured in this case. In our series, only 17% of the functional patients (14 out of 84) recovered rigid erections that allowed penetration. We may infer that a longer follow-up would show a larger number of recoveries.
On evaluating the three types of observed complications, echymosis at the injection site required no special assistance by the physician in any case.
All prolonged erection episodes recorded in this series (7 patients) were controlled by puncture and drainage with or without intracavernous injection of 10 mg of complementary of a-adrenergic agonists, clorhidrate of ethylephrine, of frequent use in divers countrys in hypotensive crisis. 2 Although the percentage of prolonged erections is slightly superior to others (3,7%), 8Y21 the reason could be found in the large number of functional patients (44%) Drop-out reasons and complications in self-injection therapy A Casabe Â et al As regards ®brosis associated to VAS, two presenting variants may be discerned: (a) small subalbugineous nodules (SAN) causing neither bending nor pain; and (b) diffuse ®brosis of the cavernous bodies that may be associated to bending and/or pain as those described in the penile plastic induration PPI. SAN do not pose a serious complication, since they fail to progress to extensive ®brosis and are satisfactorily managed by discontinuing treatment transiently, though on occasion they may be ameliorated by physical therapy (gallium arsenide laser) or medical treatment (vitamin E). In this series we have used a combination of lasertherapy and vitamine E 800 mg/d in those ®ve patients with SAN and those two with PPI. The SAN disappeared in all cases.
Different results have been published by other authors who have also tried multiple physical and medical treatment in order to stabilize or improve focal or diffuse ®brosis in the cavernous bodies. 22 Extensive penile ®brosis is a relevant complication even in patients with pre-existing organic pathology, due to bending and/or pain and to the probable technical dif®culty in the case of opting for a penile prosthetic implant as alternative therapy.
The genesis of such ®brosis depends on the physic-chemical properties of the employed substance and on local penile factors as yet undetermined with accuracy, presenting a close correlation among frequency, time of use and appearance.
Out of the ®ve patients in whom this phenomenon was observed, only one presented functional pathology, who received treatment with vacuum devices; the other four patients with organic pathology were treated with physical therapy in two patients, vacuum device in one and prosthesis in the remaining one.
Like other authors, we also believe that vascular patients who have an insuf®cient pharmacological erection, though apt for penetration, may suffer penile microtraumatisms during coitus, which might foster the development of ®brosis. 23 Cases of subalbugineous nodules discontinued treatment transiently, carrying on currently with injections (Table 3) .
In 170 patients self-injected with a mean of 0.36 ml of a triple VAS mixture, Govier et al 8 recorded 4.2% of ®brosis, 3.5% of pain and 1.7% of prolonged erections.
In a series of 116 cases, Bennett et al 21 used a triple VAS mixture dose of 0.25 ml in patients with arterial, venous or diabetic pathology, and a dose of 0.1±0.125 ml in those with neurological pathology, reporting only two cases of pain, one of prolonged erection but none of ®brosis. 21 The low incidence of ®brosis should not lead the urologist to minimize care for its prevention, periodic control and treatment, informing the patient of this contingency at the beginning of the VAS program.
We believe that periodic self-examination of the penis is extremely useful for early detection of penile scars.
The TRIMIX solution employed failed to present any collateral effects other than those already observed with other vasoactive drugs. 1, 2, 11, 16, 17, 24 Self-injection therapy with VAS affords a valid treatment alternative in patients with SED of functional and organic origin, even though the latter show a greater tendency to discontinue the VAS program.
Future investigations will no doubt evaluate, on one hand, whether VAS program discontinuance due to insuf®cient response is caused by actual refractoriness to vasoactive drugs or to improper VAS use or dose, and on the other hand, whether functional patients with sexual therapy participating in a VAS program present a lower percentage of desertion.
Conclusions
The TRIMIX solution affords a useful therapeutic alternative for the treatment of sexual erectile dysfunction arising from a functional or organic cause, with a low rate of complications.
In this series half of the patients on the VAS program discontinued treatment largely due to causes unrelated to erectile response.
Patients with erectile impairment of functional origin seemed to be more liable to make up the inactive follow-up group, to recover spontaneous erections suitable for penetration and to reduce signi®cantly the dose employed along treatment. Drop-out reasons and complications in self-injection therapy A Casabe Â et al
